Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03XSJ
|
|||
| Former ID |
DAP001076
|
|||
| Drug Name |
Buclizine
|
|||
| Synonyms |
Bucladin; Buclifen; Buclina; Buclizina; Buclizinum; Buclodin; Histabuticine; Histabutizine; Histabutyzine; Hitabutyzyne; Posdel; Softran; Vibazine; Aphilan R; Buclizine dihydrochloride; Buclizine hydrochloride; Component of Softran; Histabutyzine dihydrochloride; Histabutyzine hydrochloride; Vibazine hydrochloride; AH 2526; UCB 4445; Aphilan-R base; Buclina (TN); Buclizina [INN-Spanish]; Buclizine (INN); Buclizine [INN:BAN]; Buclizine, hydrochloride; Buclizinum [INN-Latin]; Component of Bucladin-S; Migraleve (TN); Buclizine Hydrochloride (*dihydrochloride*); Piperazine, 1-[(4-chlorophenyl)phenylmethyl]-4-[[4-(1,1-dimethylethyl)phenyl]methyl]-, dihydrochloride; Piperazine, 1-((4-chlorophenyl)phenylmethyl)-4-((4-(1,1-dimethylethyl)phenyl)methyl)-(9CI); 1-(4-Tert-butylbenzyl)-4-((4-chlorophenyl)(phenyl)methyl)piperazine; 1-(4-tert-Butylbenzyl)-4-[(4-chlorophenyl)(phenyl)methyl]piperazine; 1-(p-tert-Butylbenzyl)-4-(4-chloro-alpha-phenylbenzyl)piperazine; 1-[(4-chlorophenyl)(phenyl)methyl]-4-{[4-(1,1-dimethylethyl)phenyl]methyl}piperazine; 1-[(4-tert-butylphenyl)methyl]-4-[(4-chlorophenyl)-phenylmethyl]piperazine
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Nausea [ICD-11: MD90; ICD-10: R11] | Approved | [1], [2] | |
| Therapeutic Class |
Antihistamines
|
|||
| Company |
McNeil Laboratories
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C28H33ClN2
|
|||
| Canonical SMILES |
CC(C)(C)C1=CC=C(C=C1)CN2CCN(CC2)C(C3=CC=CC=C3)C4=CC=C(C=C4)Cl
|
|||
| InChI |
1S/C28H33ClN2/c1-28(2,3)25-13-9-22(10-14-25)21-30-17-19-31(20-18-30)27(23-7-5-4-6-8-23)24-11-15-26(29)16-12-24/h4-16,27H,17-21H2,1-3H3
|
|||
| InChIKey |
MOYGZHXDRJNJEP-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 82-95-1
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
9979, 794464, 4950544, 8154362, 10319910, 10536702, 11406399, 14982780, 29225678, 46507608, 48415654, 50011559, 51091869, 56464104, 57323667, 80423327, 85209672, 92714615, 103815028, 104312895, 117462729, 124971520, 126629482, 126687993, 127339715, 127339716, 127339717, 128627085, 134338333, 134971257, 137156390, 139029317, 141867232, 152101582, 160963701, 178103710, 179225553, 198993589, 223657303, 226415328, 241151389, 250092432
|
|||
| ChEBI ID |
CHEBI:3205
|
|||
| SuperDrug ATC ID |
R06AE01
|
|||
| SuperDrug CAS ID |
cas=000082951
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Histamine H1 receptor (H1R) | Target Info | Antagonist | [3] |
| KEGG Pathway | Calcium signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Inflammatory mediator regulation of TRP channels | ||||
| Panther Pathway | Histamine H1 receptor mediated signaling pathway | |||
| Reactome | Histamine receptors | |||
| G alpha (q) signalling events | ||||
| WikiPathways | Monoamine GPCRs | |||
| GPCRs, Class A Rhodopsin-like | ||||
| IL-4 Signaling Pathway | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7134). | |||
| REF 2 | Drug information of Buclizine, 2008. eduDrugs. | |||
| REF 3 | Toxicologic and clinical appraisal of buclizine, a new antihistaminic compound. J Allergy. 1956 Jan;27(1):63-7. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.